INTRODUCTION
In the recent years, a growing body of evidence has demonstrated extra-skeletal associations of both vitamin D (25-OH-D)(1-3) and parathyroid hormone (PTH) (4) (5) (6) , with particular focus on their metabolic implications. Several studies have suggested that low levels of vitamin D may play a role in the development of type 2 diabetes (T2DM) (7) (8) (9) . Indeed, in a meta-analysis of 21 studies, the circulating level of 25-OH-D was inversely associated with the risk of future T2DM (7) . Furthermore, deterioration in beta-cell function has been suggested as a pathophysiologic mechanism through which lower vitamin D may increase the risk of T2DM (10) (11) . Previous studies have also reported that increased PTH is associated with insulin resistance (12) and metabolic syndrome (4;13), and deterioration of insulin sensitivity and beta-cell function has been described in hyperparathyroid states (14) . Conversely, however, many investigators have questioned the association of vitamin D and PTH with glucose metabolism, particularly in light of several observational studies (13;15-18 ) and interventional trials (1;19-21) that have been either negative or showed only modest beneficial effects of vitamin D supplementation on glucose homeostasis.
A possible explanation for this conflicting evidence is that previous studies have generally evaluated the respective metabolic implications of vitamin D and PTH in isolation, rather than considering both hormones together as a reflection of the status of the PTH-vitamin D axis. Indeed, for the comprehensive assessment of many endocrine axes (e.g. thyroid), it is often necessary to consider both upstream regulators (e.g. thyroid-stimulating hormone) and downstream effector hormones (e.g. thyroxine) in conjunction with one another. Moreover, in the case of vitamin D, the 25-OH-D concentration that provides maximal PTH suppression is widely variable, suggesting that there is an individual threshold for the serum 25-OH-D concentration below which PTH rises (22) . In this context, we hypothesized that combined 4 assessment of PTH and 25-OH-D together may be needed for optimal evaluation of the impact of vitamin D status on glucose metabolism. Specifically, it may be that glucose metabolism is only adversely affected when circulating 25-OH-D falls to a level that causes PTH to rise, reflecting true functional vitamin D inadequacy. Thus, our objective in this study was to collectively evaluate vitamin D and PTH in relation to changes over time in beta-cell function, insulin sensitivity and glycemia in a cohort of subjects reflecting a broad range of diabetic risk.
METHODS

Participants
This study was performed in the setting of a prospective observational cohort consisting of women representing the full spectrum of glucose tolerance in a recent pregnancy (from normal to gestational diabetes mellitus (GDM)), who thereby have a broad range of risk for the future development of pre-diabetes and T2DM in the years after delivery (23) (24) (25) . This cohort provided a model for studying the longitudinal relationship between vitamin D/PTH and glucose metabolism in the first year postpartum for two reasons: (i) lactating women in the first year postpartum in Toronto, Canada (latitude 43°42′N) are a population at risk for vitamin D deficiency/insufficiency and (ii) the range of future diabetic risk within this cohort has been shown to manifest in changes in beta-cell function, insulin sensitivity, and glycemia between 3-and 12-months postpartum (23;26).
As previously described (23-25), the women comprising this cohort are recruited at the time of antepartum screening for GDM in late 2 nd trimester and undergo metabolic characterization at recruitment and at both 3-months and 12-months postpartum. At our institution, women are screened for GDM by 50g glucose challenge test (GCT) in late 2 nd trimester, followed by referral for diagnostic oral glucose tolerance test (OGTT) if the GCT 5 is abnormal. In this cohort study, women are recruited either before or after the GCT, and all participants undergo a 3-hour 100g OGTT for determination of GDM status (regardless of the GCT result)(27). The resultant cohort thus reflects the full spectrum of glucose tolerance in pregnancy from normal to GDM, which translates to a gradient of future risk for postpartum progression to pre-diabetes and T2DM. For this cohort study, participants return to the clinical investigation unit at both 3-and 12-months postpartum to undergo repeat metabolic characterization, including evaluation of glucose tolerance by 2-hour 75g OGTT. 
Study Visits at 3-and 12-months Postpartum
At the study visits at 3-and 12-months postpartum, interviewer-administered questionnaires were completed including assessment of current medications/supplements, duration of breastfeeding, and physical activity. As previously described (26), physical activity was assessed by the validated Baecke questionnaire. This instrument measures total physical activity and its component domains of sport-related physical activity (sport index), non-sport leisure-time activity (leisure-time index), and occupation-associated activity (work index). Work index is not measured at 3-months postpartum, as most women would not yet have returned to their usual occupation at that time. At each study visit, physical examination was performed including measurement of weight and waist circumference.
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Laboratory Measurements and Physiologic Indices
Vitamin D status was assessed with measurement of serum 25-OH-D by competitive electrochemiluminescent immunoassay on the Roche Modular E170 (Catalogue number 05894913190; Laval,Canada). This assay has a lower reporting limit of 8 nmol/l. Serum PTH was measured using an electrochemiluminescence immunoassay on the Roche Modular E170
Analyzer (Catalogue number 11972103122; Laval,Canada), which has a detection range from 0.6 to 530 pmol/L.
All OGTTs at 3-and 12-months postpartum were performed in the morning after overnight fast. Venous blood samples were drawn for the measurement of glucose and specific insulin at fasting and at 30-, 60-, and 120-minutes following the ingestion of the glucose load, as previously described (23-24).
At each OGTT, current glucose tolerance status was determined according to Canadian Diabetes Association guidelines (28). Dysglycemia refers to pre-diabetes (impaired glucose tolerance, impaired fasting glucose or both) or T2DM. Area-under-the-insulin-curve (AUC ins ) and area-under-the-glucose-curve (AUC gluc ) during the OGTT were calculated using the trapezoidal rule. Insulin sensitivity was measured using the Matsuda index, an established measure of whole-body insulin sensitivity that has been validated against the euglycemic-hyperinsulinemic clamp (29). Beta-cell function was assessed on each OGTT with the Insulin Secretion-Sensitivity Index-2 (ISSI-2). ISSI-2 is a validated measure of betacell function that is analogous to the disposition index obtained from the intravenous glucose tolerance test (ivGTT)(30-31). ISSI-2 has been directly validated against the disposition index from the ivGTT, with which it exhibits stronger correlation than do other OGTTderived measures of beta-cell function (31), and has been used to measure beta-cell function 7 in several previous studies, including both clinical trials and observational studies (10;23;32-35) . ISSI-2 is defined as the product of (i) insulin secretion measured by the ratio of the areaunder-the-insulin-curve to the area-under-the-glucose-curve and (ii) insulin sensitivity measured by Matsuda Index (30-31).
Statistical Analyses
All analyses were conducted using SAS 9.1 (SAS Institute, Cary,NC). Continuous variables were tested for normality of distribution, and natural log transformations of skewed variables were used, where necessary, in subsequent analyses.
Participants were initially stratified into groups according to (i) To evaluate whether these vitamin D and PTH groups at 3-months postpartum predict insulin sensitivity, beta-cell function and glycemia at 12-months postpartum, multiple linear regression models were constructed with metabolic outcomes of insulin sensitivity (Matsuda index), beta-cell function (ISSI-2) and glycemia (fasting glucose and 2-hr glucose) at 12-months postpartum as dependent variables (Table 2 ). In each case, Model 1 was adjusted for risk factors for diabetes (age, ethnicity, family history of diabetes, previous GDM, body mass 8 index (BMI) at 3-months) and baseline levels of the outcome. The subsequent models were further adjusted for possible confounders that could impact the association of vitamin D/PTH and the metabolic outcomes: (Model 2) duration of breastfeeding; and (Model 3) total physical activity and season of blood collection. The models were tested for collinearity of covariates using the variance inflation factor, which confirmed no significant collinearity.
Sensitivity analyses were performed with adjustment for use of calcium and vitamin D supplements, smoking status, and change in BMI between 3-and 12-months postpartum. In addition, all analyses were repeated after excluding the 19 participants with PTH above the upper limit of the laboratory normal range (6.5 pmol/l).
To evaluate the combined impact of vitamin D status and PTH tertile at 3-months on future glucose tolerance, we evaluated the prevalence of dysglycemia (pre-diabetes or diabetes) at 12-months postpartum in groups defined by both vitamin D status and PTH using With this approach (38) (39) (40) , the following three measures of biological interaction are calculated to quantify the amount of interaction on a multiplicative scale: the relative excess 9 risk due to interaction (RERI), the attributable proportion due to interaction (AP), and the synergy index (S). RERI can be interpreted as the risk that is additional to that which is to be expected on the basis of addition of the odds ratios (OR) under exposure, calculated as the difference between the expected risk and the observed risk (RER1 = OR 12 -OR 1 -OR 2 + 1).
AP can be interpreted as the proportion of disease that is due to interaction amongst persons with both exposures (AP = RER1/OR 12 ). S can be interpreted as the excess risk from both exposures in the setting of interaction, relative to the risk from exposure without interaction
As previously described (37-38), RERI=0, AP=0 and S=1 indicate the absence of biological interaction.
Using ANCOVA, we compared the percentage change from 3-to 12-months postpartum for insulin sensitivity (Matsuda index), beta-cell function (ISSI-2) and glycemia (fasting glucose and 2-hour glucose) between these four vitamin D/PTH groups, adjusted for age, ethnicity, family history of diabetes, previous GDM, and BMI at 3-months ( Figure 4 ).
Finally, sequentially-adjusted multiple linear regression models (Table 3) were constructed with Matsuda index, ISSI-2, fasting glucose and 2-hour glucose at 12-months postpartum as the outcomes using the same approach to covariate adjustment as described earlier for Table   2 .
RESULTS
The study population consisted of 494 women aged 34.8±4.3 years. There were no women with renal disease or other serious medical co-morbidities. We first evaluated the respective metabolic implications of their vitamin D status (Section I) and their PTH status (Section II), in turn, before considering both vitamin D and PTH together (Section III).
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(I) Vitamin D Status: cross-sectional associations Table 1 shows baseline (3-months postpartum) characteristics of the participants stratified into the following 3 groups based on their vitamin D status: vitamin D deficient (n=161; 33% of study population), insufficient (n=178; 36%), and sufficient (n=155; 31%).
As anticipated, the groups differed in ethnicity (P<0.001) with the vitamin D deficient group having the greatest proportion of non-white ethnicity (39.8%). In addition, the vitamin D deficient group had higher prevalence rates of family history of diabetes (P=0.04) and current smoking (P<0.008), and lower levels of physical activity at 3-months postpartum (all P<0.03).
Metabolically, BMI (P<0.001) and waist circumference (P=0.03) differed across the groups, with both being highest in the deficient group. Consistent with these differences in adiposity, the vitamin D groups also differed with respect to insulin sensitivity, beta-cell function and glycemia at 3-months postpartum. Specifically, there was a stepwise decrease in Matsuda index (P<0.001) and ISSI-2 (P=0.04) from the sufficient to insufficient to deficient group, coupled with an analogous progressive increase in fasting glucose (P<0.001) and 2-hour glucose (P=0.002) across these groups.
Vitamin D Status: longitudinal covariate-adjusted analyses
On multiple linear regression analyses (Table 2) Table 1 , the study population was also stratified into tertiles based on serum PTH at 3-months postpartum. In contrast to the vitamin D groups, these PTH groups did not differ in ethnicity, family history of diabetes, and current smoking. Leisure-time index was the only physical activity measure that differed between the PTH tertiles and was lowest in the 3 rd tertile (P=0.03). As expected, 25-OH-D differed across the groups (P<0.001).
In the same way as observed across the vitamin D groups, BMI and waist differed across the PTH tertiles, being highest in the 3 rd tertile (both P<0.001). In addition, insulin sensitivity progressively decreased (P<0.001) and fasting glucose increased (P=0.004) from the 1 st to 2 nd to 3 rd tertile. ISSI-2 was lowest in the 3 rd tertile but the overall comparison across the groups did not reach significance (P=0.06).
PTH Status: longitudinal covariate-adjusted analyses
On multiple linear regression analyses (Table 2) , the 2 nd tertile of PTH at 3-months postpartum did not independently predict insulin sensitivity, beta-cell function, fasting glucose or 2-hour glucose at 12-months, as compared to the (reference) 1 st tertile. However, the 3 rd tertile of PTH at 3-months independently predicted lower insulin sensitivity (P=0.008) and higher 2-hour glucose (P=0.007) nine months later. Finally, we performed multiple linear regression analyses to evaluate the longitudinal associations between combined vitamin D/PTH status at 3-months postpartum and metabolic outcomes, after full covariate adjustment. As shown in Table 3 , vitamin D deficiency/insufficiency accompanied by PTH in the 3 rd tertile was the only group that independently predicted lower insulin sensitivity (P=0.01) and beta-cell function (P=0.008), and increased fasting glucose (P=0.03) and 2-hour glucose (P=0.002) at 12-months postpartum, as compared to the reference group (Table 3) for these inconsistencies such as differences in study populations, diverse methodologies in the assessment of beta-cell function and insulin sensitivity, and the potential impact of confounders (such as obesity and outdoor physical activity). However, the results of the current study suggest that the lack of careful documentation of the PTH-vitamin D axis may in part explain the contradictory findings of these previous reports.
Our analyses demonstrate that vitamin D deficiency/insufficiency of sufficient biologic impact to result in an increase in PTH was independently associated with
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dysglycemia, declining insulin sensitivity and beta-cell dysfunction. These data raise the possibility that previous randomised controlled trials failed to detect a robust effect of vitamin D supplementation on glucose metabolism because they were not performed in the specific patient population that would most benefit from this intervention. In conclusion, we demonstrate that PTH status needs to be considered when 
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